ProMIS Neurosciences (NASDAQ:PMN) Shares Up 1.5%

ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares were up 1.5% on Friday . The stock traded as high as $1.98 and last traded at $1.98. Approximately 1,032 shares traded hands during trading, a decline of 97% from the average daily volume of 37,766 shares. The stock had previously closed at $1.95.

ProMIS Neurosciences Stock Up 1.5 %

The company has a market capitalization of $37.54 million, a PE ratio of -1.75 and a beta of 0.67. The company’s 50 day moving average is $2.04 and its two-hundred day moving average is $1.78.

ProMIS Neurosciences (NASDAQ:PMN) last posted its earnings results on Monday, April 1st. The company reported ($0.09) earnings per share for the quarter. Analysts forecast that ProMIS Neurosciences, Inc. will post -1.11 EPS for the current year.

Hedge Funds Weigh In On ProMIS Neurosciences

An institutional investor recently bought a new position in ProMIS Neurosciences stock. Affinity Asset Advisors LLC acquired a new position in ProMIS Neurosciences, Inc. (NASDAQ:PMN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 265,958 shares of the company’s stock, valued at approximately $527,000. Affinity Asset Advisors LLC owned approximately 3.10% of ProMIS Neurosciences as of its most recent SEC filing. 50.13% of the stock is currently owned by institutional investors.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.